HOMEPostContact Us
Posted October 03. 2013 12:53PM

Manch-based Boston Therapeutics closes $5.3M placement of common stock, warrants

Click headline or here to open angled item
Proceeds of the offering will be used to fund additional clinical trials for PAZ320, a non-systemic chewable drug designed to reduce the elevation of postprandial glucose or post-meal blood sugar for treatment of patients with Type 2 diabetes, and for general corporate purposes.